secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2026-09-16T11:00:44+00:00
Accession:  0001683168-26-007181
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic to acquire Santersus in all-stock deal; combined company to trade as SNTS
--------------------------------------------------------------------------------

- Share exchange: Xenetic acquires all Santersus shares; Santersus holders to own ~85% of combined company.
- Combined company to rename Santersus Bio, Inc. and list on Nasdaq under ticker SNTS.
- Post-close board: 8 members (6 Santersus, 2 Xenetic); Santersus CEO James Ladtkow to lead.
- Deal includes $500,000 termination fee and 180-day lock-up for officers/directors/stockholders.
- Pipeline: four first-in-class programs incl. sepsis and SLE with FDA Breakthrough Device Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/0001683168-26-007181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer